日韩av大片在线观看欧美成人不卡|午夜先锋看片|中国女人18毛片水多|免费xx高潮喷水|国产大片美女av|丰满老熟妇好大bbbbbbbbbbb|人妻上司四区|japanese人妻少妇乱中文|少妇做爰喷水高潮受不了|美女人妻被颜射的视频,亚洲国产精品久久艾草一,俄罗斯6一一11萝裸体自慰,午夜三级理论在线观看无码

The Neurofilament Light Chain （NfL）, a ~68 kDa protein encoded by the NEFL gene, is a critical structural component of the neuronal cytoskeleton, predominantly expressed in large myelinated axons of the central and peripheral nervous systems. As part of the neurofilament family （including NfM and NfH chains）, NfL forms heteropolymers that stabilize axonal structure, regulate axon diameter to modulate nerve conduction velocity, and facilitate intracellular transport by acting as a scaffold for organelles and signaling molecules. Its release into biofluids （e.g., cerebrospinal fluid and blood） following neuronal injury or degeneration has established NfL as a highly sensitive, disease-agnostic biomarker of neuroaxonal damage. Elevated NfL levels correlate with diverse neurological conditions, including neurodegenerative diseases （Alzheimer’s, Parkinson’s, ALS）, neuroinflammatory disorders （multiple sclerosis, neuromyelitis optica）, stroke, and traumatic brain injury. Notably, NfL rises before clinical symptoms emerge, enabling early detection, while baseline concentrations predict disease progression and outcomes. Reductions in NfL levels are increasingly used to monitor therapeutic efficacy in clinical trials, such as antisense oligonucleotide therapies for ALS. Ultrasensitive assays like Simoa allow noninvasive blood-based quantification, enhancing its utility for longitudinal monitoring. With high sensitivity, accessibility, and broad applicability, NfL has become pivotal in advancing diagnostics, prognostics, and personalized treatment strategies for neurological disorders.